Advertisement

Topics

Mylan partners with Otsuka to commercialize tuberculosis med delamanid in high-burden countries

08:51 EDT 24 Aug 2017 | Topix

Subsidiaries of Mylan N.V. and Otsuka Pharmaceutical Co. ink an agreement to commercialize delamanid, branded as Deltyba by Otsuka, for the treatment of adults with pulmonary multidrug-resistant tuberculosis in low- and middle-income countries.

Original Article: Mylan partners with Otsuka to commercialize tuberculosis med delamanid in high-burden countries

NEXT ARTICLE

More From BioPortfolio on "Mylan partners with Otsuka to commercialize tuberculosis med delamanid in high-burden countries"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...